Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun 1;67(11):919-28.
doi: 10.2146/ajhp100068.

Projecting future drug expenditures--2010

Affiliations

Projecting future drug expenditures--2010

James M Hoffman et al. Am J Health Syst Pharm. .

Abstract

Purpose: Drug expenditure trends in 2008 and 2009, projected drug expenditures for 2010, and factors likely to influence drug expenditures are discussed.

Summary: Various factors are likely to influence drug expenditures in 2010, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, drug safety concerns, and comparative effectiveness research. The increasing availability of important generic drugs continues to moderate growth in drug expenditures. Health care reform initiatives, including the potential for biosimilars legislation, will influence drug expenditures in all settings. From 2007 to 2008, total U.S. drug expenditures increased by 1.8%, with total spending rising from $279.6 billion to $284.7 billion. Growth in drug expenditures in clinics declined to the lowest level in a decade, a 1.0% increase from 2007 to 2008. Hospital drug expenditures increased at a moderate rate of only 2.1% from 2007 to 2008; through the first nine months of 2009, hospital drug expenditures increased by 3.0% compared with the same period in 2008.

Conclusion: In 2010, we project a 3-5% increase in drug expenditures in outpatient settings, a 6-8% increase in expenditures for clinic-administered drugs, and a 2-4% increase in hospital drug expenditures.

PubMed Disclaimer

Similar articles

  • Projecting future drug expenditures--2009.
    Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, Matusiak L, Hunkler RJ, Schumock GT. Hoffman JM, et al. Am J Health Syst Pharm. 2009 Feb 1;66(3):237-57. doi: 10.2146/ajhp080636. Am J Health Syst Pharm. 2009. PMID: 19179637
  • Projecting future drug expenditures--2012.
    Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND, Vermeulen LC, Schumock GT. Hoffman JM, et al. Am J Health Syst Pharm. 2012 Mar 1;69(5):405-21. doi: 10.2146/ajhp110697. Am J Health Syst Pharm. 2012. PMID: 22345420
  • Projecting future drug expenditures: 2011.
    Doloresco F, Fominaya C, Schumock GT, Vermeulen LC, Matusiak L, Hunkler RJ, Shah ND, Hoffman JM. Doloresco F, et al. Am J Health Syst Pharm. 2011 May 15;68(10):921-32. doi: 10.2146/ajhp100712. Am J Health Syst Pharm. 2011. PMID: 21546644
  • National trends in prescription drug expenditures and projections for 2016.
    Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, Hunkler RJ, Vermeulen LC. Schumock GT, et al. Am J Health Syst Pharm. 2016 Jul 15;73(14):1058-75. doi: 10.2146/ajhp160205. Epub 2016 May 11. Am J Health Syst Pharm. 2016. PMID: 27170624 Review.
  • Projecting future drug expenditures--2005.
    Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM. Hoffman JM, et al. Am J Health Syst Pharm. 2005 Jan 15;62(2):149-67. doi: 10.1093/ajhp/62.2.149. Am J Health Syst Pharm. 2005. PMID: 15700889 Review.

Cited by

Publication types